BMEA News and Press, Biomea Fusion Inc. From 06/03/24

REDWOOD CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically de...

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases a...

2024-05-09 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-03 01:50:22 ET More on Biomea Fusion Why Biomea Fusion Is A 'Hold': A Bet On Diabetes And Oncology Research Biomea Fusion drops as JPMorgan downgrades on data for lead asset Seeking Alpha’s Quant Rating on Biomea Fusion Historical earnings data...

Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healt...

2024-04-15 17:21:24 ET Gainers: Macatawa Bank Corporation ( MCBC ) +38% . Biomea Fusion ( BMEA ) +5% . The RealReal ( REAL ) +4% . Cartesian Therapeutics ( RNAC ) +3% . Construction Partners ( ROAD ) +3% . Losers: Poseida...

2024-04-02 13:18:01 ET Biomea Fusion ( NASDAQ: BMEA ) shares fell on Tuesday as JPMorgan downgraded the biotech to Neutral from Overweight citing  its financial issues and newly released data for the company’s lead asset BMF-219.... Read the full article on Seeking...

REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically d...

2024-04-01 10:06:14 ET More on Biomea Fusion Why Biomea Fusion Is A 'Hold': A Bet On Diabetes And Oncology Research Seeking Alpha’s Quant Rating on Biomea Fusion Read the full article on Seeking Alpha For further details see: Biomea Fusion GAAP EPS...

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in COVALENT-112 both demonstrated early signs of clinical activity with improved measures of be...